



Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

1

		Complete if Known	
Application Number		10/736,188	
Filing Date		December 15, 2003	
First Named Inventor		Katherine S. Bowdish	
Art Unit		1643	
Examiner Name		B. Duffy	
Attorney Docket Number		ALEX-P03-060	

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
AA7	US-2003/0017491	01-23-2003	Shi et al.		
AA8	US2002/0031515	03-14-2002	Caligiuria et al.		

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number-Kind Code ⁴ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁵
	B4	WO-02/059280	08-01-2002	Alexion Pharmaceuticals, Inc.		

Examiner Signature

Date Considered

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue numbers, publisher, city and/or country where published.	T ²
CN3		Goreczynski, "Evidence for an Immunoregulatory Role of CX2 with its Counter Ligand (CX2L) in the Regulation of Transplant Rejection, Cell Loss, Autoimmunity and Tumor Growth," <i>Archicum Immunologica et Therapica Experimentalis</i> , 2001, 49, 303-309.	
CO3		Sahin et al., "New monoclonal antibody specific for a 6.5 kDa glycoprotein which presents mainly on a B cell of chronic lymphocytic leukemia (CLL)" <i>Immunology Letters</i> , 2001, 76, 1-6.	

Examiner Signature

/Brad Duffy/

Date Considered

06/12/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.